Orin
CENYSE·Chemicals - Specialty

Celanese Corporation CE

Market cap $5.3BP/E —no earnings to divide byGross margin 20.2%Reports Thu 5 Nov, after the close
$48.50
+0.94 (+1.98%)live 11:20 ET
52-wk $35.13 – $70.70
Watch
Orin's take
0.62conviction · moderate
Refreshed 22 Aug · take v5. A new filing or a print queues the next refresh.

Celanese remains a hold as the operational turnaround is real but the balance sheet overhang persists. FY2025 operating income recovered to $767M from -$697M in FY2024, Q2 2026 earnings beat estimates on pricing and commercial execution, and a cluster buy by three insiders (CFO Kyrish, SVP Murray, SVP Duffie) between August 11–14, 2026 signals internal confidence.

However, two consecutive years of net losses (-$1.165B in FY2025, -$1.522B in FY2024), $12.9B in total debt against $4.0B equity, and an EV/EBITDA of 91.6x versus a peer median of 10.7x keep the risk/reward balanced. The stock at $46.26 trades below both its 50-day ($46.96) and 200-day ($50.33) moving averages, and while the VIGOR robotics partnership and H2 2026 Acetyl Chain moderation guidance are encouraging, sustained profitability and visible deleveraging are needed before upgrading.

What could go wrong

  • Leverage and solvency. Total debt of $12.934B against stockholders' equity of $4.049B as of FY2025 creates a highly leveraged capital structure; any further deterioration in margins or cash flow could pressure refinancing terms and credit ratings.
  • Persistent net losses. Net income was -$1.165B in FY2025 and -$1.522B in FY2024, with EPS of -$10.64 and -$13.93 respectively; despite operating income recovery, bottom-line profitability has not returned.
  • Revenue decline continues. Revenue fell 7.16% YoY in FY2025 to $9.544B, following a 6.03% decline in FY2024, indicating ongoing demand or pricing pressure in core segments.
  • Valuation disconnect. EV/EBITDA of 91.6x is 757% above the peer median of 10.7x, meaning the market prices in significant debt and earnings risk despite the 0.52x P/S discount to peers.

What would change my mind

Return to GAAP profitability. Celanese reports a full quarter of positive net income and positive diluted EPS, confirming the operating recovery reaches the bottom line.bullish
Material debt reduction. Total debt declines below $11B with a corresponding improvement in the equity-to-debt ratio, demonstrating deleveraging commitment.bullish
Gross margin compression. Gross margin falls below the FY2025 level of 18.77%, signaling that pricing gains are not offsetting input cost or demand pressures.bearish
Stock reclaiming 200-day MA. CE closes above $50.33 (200-day MA) on sustained volume, confirming technical trend reversal and reducing downside momentum risk.bullish

Where this comes from: FMP annual fundamentals, fiscal year ended 2025-12-31 · FMP annual fundamentals, fiscal year ended 2025-12-31 · FMP annual fundamentals · peer_relative composite. Orin's read on CE; not advice.

Twelve months actual closes to 2026-09-24 · actual filings

Sept 25Nov 25Jan 26Mar 26May 26Jul 26

50-day average 200-day average · volume below

Largest holders · 13F Q2 2026

Money flow
FilerPositionOf fund
Norges Bank$429.8M0.0% of fund
Vanguard Portfolio Management$300.2M0.0% of fund
Vanguard Capital Management$228.5M0.0% of fund
State Street$184.6M0.0% of fund
Capital Research Global Investors$172.6M0.0% of fund
Capital World Investors$140.3M0.0% of fund

72 filers · quarter ended Q2 2026 · positions, not flows

Insiders, last 24 months: 142 Form 4 filings, net $18.1M. Of the 50 on hand, 5 were open-market purchases and 0 sales— the rest are grants, option exercises and tax withholding.

Ask Orin about CE

its filings · its transcripts · its numbers

Orin answers questions about CE from its filings, transcripts and numbers — with the source behind every claim. Your own desk starts with 3 free days, card required.

Start 3 free days →

Where it trades

· Basic Materials
MetricNowOwn medianSector
EV/EBITDA92.4×——
P/S0.54×——
P/B1.3×——
What the price assumes

-8.1%

free-cash-flow growth every year for 10 years, discounted at 10%, is what today’s price implies — starting from $0.8B of trailing free cash flow. It is an assumption the market is making, not a forecast Orin is making.

What Wall Street published

37 firms · 2026-09-24
Consensus target

$60

$50 – $75 · +24% against today's price

How they rate it
  • 11 buy or overweight
  • 22 hold
  • 4 underweight or sell

The analysts’ consensus and their own ratings, not Orin’s. A target is a twelve-month opinion published by the firm that wrote it.

Against the companies it is compared to

median P/E 27.2× of 4 peers
CompanyMarket capP/EEV/EBITDAGrossNetROE
CECelanese Corporation$5B—92.4×20.2%-12.0%-29%
ASHAshland Inc.$3B60.6×10.8×29.4%2.8%3%
CBTCabot Corp.$4B21.8×7.4×22.9%5.2%12%
FULH.B. Fuller Company$3B13.7×8.9×32.9%5.6%10%
HWKNHawkins, Inc.$3B32.6×16.6×22.3%7.3%15%

The median is of the 4 peers listed above and nothing else — check it against the column. The peer set is the vendor’s, so a company can appear here that a person would not have chosen.

What it has traded at

P/E by fiscal year
FY14 14.9×FY23 8.6×

What its sector has traded at

Basic Materials
FY14 23.8×FY26 28.6×

Two scales, drawn separately on purpose: a sector median and one company’s multiple are not the same number and putting them on one axis invites a comparison neither series supports.

Every estimate on one scale

price $48.50
52-week range$35 – $71
Analyst targets$50 – $75

The vertical rule is the current price. Ranges and point estimates are the backend’s, published as they were calculated; an arrow means the estimate sits beyond this scale, and its number is on the right.